What are the malignancies and vasculitides associated with relapsing polychondritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Malignancies and Vasculitides Associated with Relapsing Polychondritis

Relapsing polychondritis is associated with hematologic malignancies—particularly myelodysplastic syndrome and lymphomas—as well as ANCA-associated vasculitides, with large vessel arteritis being a rare but prognostically significant complication.

Associated Malignancies

Hematologic Malignancies (Most Common)

Myelodysplastic syndrome (MDS) is the most frequently associated malignancy with relapsing polychondritis 1, 2. This association is particularly important because:

  • MDS occurs more frequently with relapsing polychondritis than with other vasculitides 1
  • The association is especially common in men over 50 years of age 3
  • This combination may represent a distinct phenotype with worse prognosis 3
  • Screen for MDS when cutaneous and mucosal manifestations coexist with polychondritis 1

Lymphomas

Several types of lymphoma have been documented in association with relapsing polychondritis 2:

  • Non-Hodgkin lymphoma (including splenic marginal zone B-cell lymphoma) 4, 2
  • Hodgkin lymphoma 2
  • Orbital mucosa-associated lymphoid tissue (MALT) lymphoma 2

The temporal relationship varies: polychondritis may precede lymphoma, occur simultaneously, or develop after lymphoma diagnosis and treatment 2. Some cases suggest polychondritis may represent a paraneoplastic phenomenon of underlying hematologic malignancies 2.

VEXAS Syndrome Consideration

In older adults (particularly men >50 years) presenting with relapsing polychondritis features, consider VEXAS syndrome 5, 6. Key red flags include:

  • Macrocytic anemia and unexplained cytopenias
  • Refractory inflammation despite treatment
  • Bone marrow showing cytoplasmic vacuoles in myeloid precursors
  • UBA1 gene mutation on sequencing 5

This is critical because VEXAS mimics relapsing polychondritis but requires different management approaches 6.

Associated Vasculitides

ANCA-Associated Vasculitides

Any of the ANCA-associated vasculitides can accompany relapsing polychondritis, though this is rare 7:

  • Eosinophilic granulomatosis with polyangiitis (EGPA) - documented coexistence 7
  • Granulomatosis with polyangiitis (GPA)
  • Microscopic polyangiitis (MPA)

Large Vessel Arteritis

Large vessel arteritis is a rare but prognostically important association 8. Specific features include:

  • Stenosis of internal carotid arteries
  • Involvement of central nervous system vessels
  • Negatively affects prognosis 8
  • Requires early detection and aggressive treatment 8

Clinical pearl: Auscultate for carotid bruits in patients with relapsing polychondritis, and consider vascular imaging (MR angiography) to detect large vessel involvement 8.

Small Vessel Vasculitis

Cutaneous vasculitis can occur as a dermatologic manifestation 1:

  • Papulonodular lesions
  • Mucosal aphthous lesions
  • Vasculitis without leukocytoclastic features on biopsy 1

Clinical Approach to Screening

When diagnosing relapsing polychondritis, systematically evaluate for associated conditions:

  1. Complete blood count with differential: Look for cytopenias, macrocytosis, or eosinophilia
  2. Bone marrow examination: If cytopenias or macrocytosis present, especially in men >50 years 5, 3
  3. ANCA testing: If systemic vasculitis features present 7
  4. Vascular examination: Auscultate for bruits; consider imaging if large vessel involvement suspected 8
  5. UBA1 sequencing: In refractory cases with cytopenias and bone marrow vacuoles 5

The presence of myelodysplasia or VEXAS syndrome fundamentally changes treatment strategy and worsens prognosis 3, making early identification essential for appropriate management decisions.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.